Immunological basis in the pathogenesis and treatment of bladder cancer

References

• Simons MP, Nauseef WM, Griffith TS. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol Res 2007;39:79-93
   PubMedGoogle Scholar
• American Cancer Society. Cancer facts & figures 2014. Atlanta: American Cancer Society; 2014. Available from: www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf [Last accessed 7 June 2014]
   Google Scholar
• Rossi R, Lichtner M, Iori F, et al. Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy. Arch Ital Urol Androl 2013;85(4):157-63
   PubMedGoogle Scholar
• Van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol cancer Res 2012;10(8):995-1009
   PubMedGoogle Scholar
• Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-12
   PubMed Web of Science ®Google Scholar
• Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009;106(33):14016-21
   PubMed Web of Science ®Google Scholar
• Kompier LC, Lurkin I, van der Aa MNM, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5(11):e13821
   PubMed Web of Science ®Google Scholar
• Apolo AB, Milowsky M, Bajorin DF. Clincial states model for biomarkers in bladder cancer. Future Oncol 2009;5(7):977-92
   PubMedGoogle Scholar
• Shariat SF, Karam Ja, Lotan Y, et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008;10(2):120-35
   PubMedGoogle Scholar
• Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160(3 Pt 1):645-59
   PubMedGoogle Scholar
• Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66(23):11271-8
   PubMed Web of Science ®Google Scholar
• Enkelmann A, Heinzelmann J, von Eggeling F, et al. Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol 2011;137(5):751-9
   PubMedGoogle Scholar
• Tachibana M, Miyakawa A, Tazaki H, et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor autocrine growth of transitional cell carcinoma of the bladder induced by. Cancer Res 1995;55:3438-43
   PubMed Web of Science ®Google Scholar
• Nieto MA, Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012;22:361-8
   PubMedGoogle Scholar
• Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol 2007;25(3):260-8
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431(7007):461-6
   PubMed Web of Science ®Google Scholar
• Stonehill W, Dmochowski R, Patterson A, et al. Risk factors for bladder tumors in spinal cord injury patients. J Urol 1996;155:1248-50
   PubMed Web of Science ®Google Scholar
• Locke JR, Hill DE, Walzer Y. Incidence of squamous cell carcinoma in patients with long-term catheter drainage. J Urol 1985;133(6):1034-5
   PubMedGoogle Scholar
• Marsh HP, Haldar NA, Bunce M, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 2003;89(6):1096-101
   PubMed Web of Science ®Google Scholar
• Welk B, McIntyre A, Teasell R, et al. Bladder cancer in individuals with spinal cord injuries. Spinal Cord 2013;51(7):516-21
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-99
   PubMed Web of Science ®Google Scholar
• Tricker AR, Stickler DJ, Chawla JC, et al. Increased urinary nitrosamine excretion in paraplegic patients. Carcinogenesis 1991;12(5):943-6
   PubMedGoogle Scholar
• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-49
   PubMed Web of Science ®Google Scholar
• Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000;82(7):1364-9
   PubMedGoogle Scholar
• Klan R, Knispel HH, Meier T. Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl) nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol 1993;119(8):482-5
   PubMedGoogle Scholar
• Spencer JD, Schwaderer AL, Becknell B, et al. The innate immune response during urinary tract infection and pyelonephritis. Pediatr Nephrol 2014;29(7):1139-49
   PubMed Web of Science ®Google Scholar
• Beetz R. May we go on with antibacterial prophylaxis for urinary tract infections? Pediatr Nephrol 2006;21(1):5-13
   PubMedGoogle Scholar
• Rahman H, Deka M. Detection & characterization of necrotoxin producing Escherichia coli (NTEC) from patients with urinary tract infection (UTI). Indian J Med Res 2014;139(4):632-7
   PubMedGoogle Scholar
• Underwood MA, Bevins CL. Defensin-barbed innate immunity: clinical associations in the pediatric population. Pediatrics 2010;125(6):1237-47
   PubMedGoogle Scholar
• Song J, Abraham SN. Innate and adaptive immune responses in the urinary tract. Eur J Clin Invest 2008;38(Suppl 2):21-8
   PubMedGoogle Scholar
• Loughman JA, Hunstad DA. Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect 2011;13(6):555-65
   PubMedGoogle Scholar
• Tittel AP, Heuser C, Ohliger C, et al. Kidney dendritic cells induce innate immunity against bacterial pyelonephritis. J Am Soc Nephrol 2011;22(8):1435-41
   PubMedGoogle Scholar
• Thumbikat P, Waltenbaugh C, Schaeffer A, et al. Antigen-specific responses accelerate bacterial clearance in the bladder. J Immunol 2006;176(5):3080-6
   PubMedGoogle Scholar
• Duell BL, Carey AJ, Tan CK, et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 2012;188(2):781-92
   PubMed Web of Science ®Google Scholar
• Khan MA, Travis LB, Lynch CF, et al. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998;7:397-403
   PubMed Web of Science ®Google Scholar
• Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm 2012;2012:1-11
   Google Scholar
• Bronte V, Gabrilovich D. Myeloid-derived suppressor cells. Nat Rev Immunol 2010
   Google Scholar
• Eruslanov E, Neuberger M, Daurkin I, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J cancer 2012;130(5):1109-19
   PubMed Web of Science ®Google Scholar
• Robinson BD, Sica GL, Liu Y-F, et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009;15(7):2433-41
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18(5):349-55
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69(4):1553-60
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166(1):678-89
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6(4):283-7
   PubMedGoogle Scholar
• Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective Bacillus Calmette–Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006;66(16):8250-7
   PubMedGoogle Scholar
• Gunes M, Gecit I, Pirincci N, et al. Plasma human neutrophil proteins-1, -2, and -3 levels in patients with bladder cancer. J Cancer Res Clin Oncol 2013;139(2):195-9
   PubMedGoogle Scholar
• Albrethsen J, Bøgebo R, Gammeltoft S, et al. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005;5:8
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158(4):1491-502
   PubMed Web of Science ®Google Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek List 2001;102(1):5-14
   PubMedGoogle Scholar
• Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012;79(5):1085-91
   PubMed Web of Science ®Google Scholar
• Hanada T, Nakagawa M, Emoto A, et al. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000;7(7):263-9
   PubMed Web of Science ®Google Scholar
• Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 2013;33(7):1478-83
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23(11):549-55
   PubMed Web of Science ®Google Scholar
• Lima L, Oliveira D, Tavares A, et al. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol 2014;32:449-57
   PubMed Web of Science ®Google Scholar
• Ajili F, Kourda N, Darouiche A, et al. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol 2013;37(1):56-61
   PubMed Web of Science ®Google Scholar
• Granata F, Frattini A, Loffredo S, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 2010;184(9):5232-41
   PubMed Web of Science ®Google Scholar
• Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 2005;117(5):701-8
   PubMed Web of Science ®Google Scholar
• Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141(1):39-51
   PubMed Web of Science ®Google Scholar
• Hofner T, Macher-Goeppinger S, Klein C, et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol 2014;32(5):678-86
   PubMed Web of Science ®Google Scholar
• Chen M-F, Lin P-Y, Wu C-F, et al. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 2013;8(4):e61901
   Google Scholar
• McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-44
   PubMed Web of Science ®Google Scholar
• Fondrevelle ME, Kantelip B, Reiter RE, et al. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 2009;27(3):268-76
   PubMed Web of Science ®Google Scholar
• Ho PL, Lay EJ, Jian W, et al. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 2012;72(13):3135-42
   PubMed Web of Science ®Google Scholar
• Wu M-L, Li H, Yu L-J, et al. Short-Term Exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One 2014;9(2):e89806
   PubMed Web of Science ®Google Scholar
• Lee SJ, Park SS, Cho YH, et al. Activation of matrix metalloproteinase-9 by TNF-alpha in human urinary bladder cancer HT1376 cells: the role of MAP kinase signaling pathways. Oncol Rep 2008;19(4):1007-13
   PubMedGoogle Scholar
• Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific. Clin Cancer Res 2001;7:23-31
   PubMedGoogle Scholar
• Beatty JD, Islam S, North ME, et al. Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer? BJU Int 2004;94(9):1377-83
   PubMedGoogle Scholar
• Shintani Y, Sawada Y, Inagaki T, et al. Intravesical instillation therapy with bacillus Calmette–Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette–Guérin immunotherapy. Int J Urol 2007;14(2):140-6
   PubMedGoogle Scholar
• Abadie V, Badell E, Douillard P, et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 2005;106(5):1843-50
   PubMed Web of Science ®Google Scholar
• Ayari C, LaRue H, Hovington H, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette–Guérin immunotherapy. Eur Urol 2009;55:1386-95
   PubMedGoogle Scholar
• Ayari C, LaRue H, Hovington H, et al. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Hum Pathol 2013;44(8):1630-7
   PubMed Web of Science ®Google Scholar
• Feyisetan O, Tracey C, Hellawell GO. Probiotics, dendritic cells and bladder cancer. BJU Int 2012;109(11):1594-7
   PubMed Web of Science ®Google Scholar
• Chen T, Wang H, Zhang Z, et al. A novel cellular senescence gene, SENEX, is involved in peripheral regulatory T cells accumulation in aged urinary bladder cancer. PLoS One 2014;9(2):e87774
   Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127(4):759-67
   PubMed Web of Science ®Google Scholar
• Furukawa J, Hara I, Nagai H, et al. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 2006;176(3):1198-203
   PubMedGoogle Scholar
• Satyam A, Singh P, Badjatia N, et al. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol 2011;29(1):58-65
   PubMedGoogle Scholar
• Reijke TM, Boer EC, Kurth KH, et al. Urinary cytokines during intravesical bacillus Calmette–Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996;155(2):477-82
   PubMedGoogle Scholar
• Perabo FG, Kamp S, Schmidt D, et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer 2001;84(10):1330-8
   PubMedGoogle Scholar
• Gruss HJ. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996;26(3):143-59
   PubMedGoogle Scholar
• Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272(51):32401-10
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Yoshida O, Miki T. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol 1999;162(6):2170-5
   PubMedGoogle Scholar
• American Cancer Society. American Cancer Society: bladder cancer. 2014. Available from: www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf [Last accessed 22 July 2014]
   Google Scholar
• Gándara L, Sandes E, Di Venosa G, et al. The natural flavonoid silybin improves the response to photodynamic therapy of bladder cancer cells. J Photochem Photobiol B 2014;133:55-64
   PubMedGoogle Scholar
• Richterstetter M, Wullich B, Amann K, et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int 2012;110:76-9
   PubMedGoogle Scholar
• Highley MS, van Oosterom AT, Maes RA, et al. Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 1999;37(1):59-73
   PubMedGoogle Scholar
• Bazarbashi S, Soudy H, Abdelsalam M, et al. Co-administration of intravesical bacillus Calmette–Guérin and interferon α-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder. BJU Int 2011;108(7):1115-18
   PubMedGoogle Scholar
• Maffezzini M, Campodonico F, Canepa G, et al. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol 2014;73(5):925-30
   PubMed Web of Science ®Google Scholar
• Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase. Lancet Oncol 2013;14(9):863-72
   PubMed Web of Science ®Google Scholar
• Koie T, Ohyama C, Hashimoto Y, et al. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol 2013;18(4):724-30
   PubMed Web of Science ®Google Scholar
• Aluwini S, van Rooij PHE, Kirkels WJ, et al. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: long-term results. Int J Radiat Oncol Biol Phys 2014;88(3):611-17
   PubMedGoogle Scholar
• Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette–Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol 2010;2010:357591
   PubMedGoogle Scholar
• Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-l) in bladder cancer patients after Bacillus Calmette – Guerin (BCG) immunotherapy. Clin Exp Immunol 1995;99:369-75
   PubMed Web of Science ®Google Scholar
• Brincks EL, Risk MC, Griffith TS. PMN and anti-tumor immunity–the case of bladder cancer immunotherapy. Semin Cancer Biol 2013;23(3):183-9
   PubMedGoogle Scholar
• Bohle A, Brandau S. Immune mechanisms in bacillus Calmette–Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-9
   PubMed Web of Science ®Google Scholar
• Jinesh GG, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol 2012;92(1):233-44
   PubMedGoogle Scholar
• Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3(6):673-82
   PubMed Web of Science ®Google Scholar
• Simons MP, O’Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008;26(4):341-5
   PubMedGoogle Scholar
• Takayama H, Nishimura K, Tsujimura A, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette–Guerin instillation. J Urol 2009;181(4):1894-900
   PubMedGoogle Scholar
• Luo Y, Blocking IL-10 enhances bacillus Calmette–Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity. Oncoimmunology 2012;1(7):1183-5
   PubMed Web of Science ®Google Scholar
• Bohle A, Gerdes J, Ulmer A, et al. Effects of local Bacillus Calmette–Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990;144:53-8
   PubMedGoogle Scholar
• Takeuchi A, Dejima T, Yamada H, et al. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette–Guerin treatment against bladder cancer. Eur J Immunol 2011;41:246-51
   PubMed Web of Science ®Google Scholar
• Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004;29(9):486-94
   PubMedGoogle Scholar
• Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994;54:3516-20
   PubMed Web of Science ®Google Scholar
• Bubenik J. Cytokine vaccines in the therapy of cancer. Pharmacol Ther 1996;69(1):1-14
   PubMedGoogle Scholar
• Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990;322(16):1129-38
   PubMed Web of Science ®Google Scholar
• Soloway MS, Murphy WM. Experimental chemotherapy of bladder cancer–systemic and intravesical. Semin Oncol 1979;6(2):166-83
   PubMedGoogle Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90(8):3539-43
   PubMed Web of Science ®Google Scholar